Serotonin–norepinephrine reuptake inhibitor
class of antidepressant drugs used in the treatment of major depressive disorder
Serotonin–norepinephrine reuptake inhibitors (SNRIs) are a class of antidepressant medications used to treat major depressive disorder (MDD), anxiety disorders, chronic neuropathic pain, fibromyalgia, and menopausal symptoms. Off-label uses include treatments for attention deficit hyperactivity disorder (ADHD) and obsessive–compulsive disorder (OCD). SNRIs are monoamine reuptake inhibitors; specifically, they inhibit the reuptake of serotonin and norepinephrine. These neurotransmitters are thought to play an important role in mood regulation. SNRIs can be contrasted with the selective serotonin reuptake inhibitors (SSRIs) and norepinephrine reuptake inhibitors (NRIs), which act upon single neurotransmitters. Since norepinephrine pathways play a role in pain modulation, SNRIs are also widely used for chronic pain conditions such as neuropathic pain and fibromyalgia.
The human serotonin transporter (SERT) and norepinephrine transporter (NET) are membrane transport proteins that are responsible for the reuptake of serotonin and norepinephrine from the synaptic cleft back into the presynaptic nerve terminal. Dual inhibition of serotonin and norepinephrine reuptake can offer advantages over other antidepressant drugs by treating a wider range of symptoms. They can be especially useful in concomitant chronic or neuropathic pain.
SNRIs, along with SSRIs and NRIs, are second-generation antidepressants.
Begin with the source’s own compact description: “Serotonin–norepinephrine reuptake inhibitor” is class of antidepressant drugs used in the treatment of major depressive disorder. The dossier treats that line as a proposition to test through Serotonin, norepinephrine and reuptake, not as a finished interpretation.
Why this record matters
The phrase “class of antidepressant drugs used in the treatment of major depressive disorder” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Sep 12, 2026. The linked authority identifier is Q2273909. None of the 0 selected statements returned an explicit reference.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Serotonin–norepinephrine reuptake inhibitor”, its source revision and the description used here.
- Expand the search: follow Serotonin–norepinephrine reuptake inhibitor primary sources, Serotonin–norepinephrine reuptake inhibitor archive and Serotonin research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Serotonin–norepinephrine reuptake inhibitor”?
- What terminology or title could unlock a more precise catalogue search?
- Which cited source is closest to the event, object or claim?
Search terms from this dossier
This entry incorporates text from “Serotonin–norepinephrine reuptake inhibitor” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.